stockrowPraxis Precision Medicines, Inc.
PRAX Healthcare Biotechnology
Praxis Precision Medicines, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8.6 million, up 249.5% from fiscal 2023.
- Revenue
- +1,349.1%
- EPS
- +13.3%
- Free cash flow
- −43.5%
Quarter to June 2026, against a year earlier
Follow PRAX
Alert me
Praxis Precision Medicines, Inc. (PRAX) Shares outstanding
Praxis Precision Medicines, Inc.'s shares outstanding at the end of fiscal 2025 was $22.5M, up 25.7% from $17.9M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $29.1M. Over the past ten years it has ranged from $86.6K (fiscal 2018) to $22.5M (fiscal 2025) — the current reading is the highest in ten years. Praxis Precision Medicines, Inc. ranks 365th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $22.5M | 25.68% |
| FY2024 | $17.9M | 171.57% |
| FY2023 | $6.6M | 114.58% |
| FY2022 | $3.1M | 8.52% |
| FY2021 | $2.8M | 374.32% |
| FY2020 | $597.0K | 484.72% |
| FY2019 | $102.1K | 17.90% |
| FY2018 | $86.6K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $29.1M | 0.86% |
| Mar 2026 | $28.9M | 28.34% |
| Dec 2025 | $22.5M | 2.40% |
| Sep 2025 | $22.0M | 2.34% |
| 23 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. compare | $143.4M |
| CYTK Cytokinetics, Incorporated compare | $132.1M |
| CORT Corcept Therapeutics Incorporated compare | $123.2M |
| SYRE Spyre Therapeutics, Inc. compare | $88.4M |
| ABVX Abivax SA Sponsored ADR compare | $79.6M |
| RYTM Rhythm Pharmaceuticals, Inc. compare | $69.0M |
| AXSM Axsome Therapeutics, Inc. compare | $52.4M |
| KRYS Krystal Biotech, Inc. compare | $30.8M |
| PRAX Praxis Precision Medicines, Inc. | $29.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item